<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id><journal-id journal-id-type="pmc">eid</journal-id><journal-title>Emerging Infectious Diseases</journal-title><issn pub-type="ppub">1080-6040</issn><issn pub-type="epub">1080-6059</issn><publisher><publisher-name>Centers for Disease Control</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11266291</article-id><article-id pub-id-type="pmc">2631682</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Engberg</surname><given-names>J.</given-names></name><email>eng@ssi.dk</email></contrib><contrib contrib-type="author"><name><surname>Aarestrup</surname><given-names>F. M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>D. E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gerner-Smidt</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nachamkin</surname><given-names>I.</given-names></name></contrib></contrib-group><aff>Department of Gastrointestinal Infections, Division of Diagnostics, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark.</aff><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2001</year></pub-date><volume>7</volume><issue>1</issue><fpage>24</fpage><lpage>34</lpage><abstract><p>The incidence of human Campylobacter jejuni and C. coli infections has increased markedly in many parts of the world in the last decade as has the number of quinolone-resistant and, to a lesser extent, macrolide-resistant Campylobacter strains causing infections. We review macrolide and quinolone resistance in Campylobacter and track resistance trends in human clinical isolates in relation to use of these agents in food animals. Susceptibility data suggest that erythromycin and other macrolides should remain the drugs of choice in most regions, with systematic surveillance and control measures maintained, but fluoroquinolones may now be of limited use in the empiric treatment of Campylobacter infections in many regions.</p></abstract></article-meta></front></article>